Stock Ratings / Health Care / TLRY / insiders

OBIO (28) SNDL (61) CGC (51) USNA (61) ⌘ Pro Terminal →

Tilray Brands Inc. (TLRY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are TLRY insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TLRY leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$2.64 -1.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Tilray Brands Inc. (TLRY) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $390.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLRY)Realized 20D OHLCV Swing Band: ±10.9%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TLRY Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TLRY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TLRY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLRY)

✓Walkthrough of TLRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TLRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.69%▼ DESCENDING CHANNEL

2026-10-30O $2.65H $2.67L $2.49C $2.64VOL 4.93M

RES: $4.36SUP: $1.72SMA50: $3.79SMA200: $5.47

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLRY Butterfly Map → + Track TLRY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TLRY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLRY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TLRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLRY)

Health Care Rank #888 of 1016 ⚔️ OBIO vs TLRY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLRY vs. OBIO, SNDL, CGC, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tilray Brands Inc. (TLRY) ranks #888 by composite RQD confidence (32/100, grade E) and #484 by equity capitalization ($390.2M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. SNDL currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with TLRY at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TLRY ACTIVE Tilray Brands Inc.	E	32/100	—	28.4%	-3.9%	-1.86%	$390.2M	Benchmark Subject
OBIO Orchestra BioMed Holdings Inc.	E	28/100	—	96.0%	-35.0%	+1.67%	$366.0M	/obio-vs-tlry →
SNDL SNDL Inc.	C-	61/100	—	—	—	+0.78%	$316.3M	/sndl-vs-tlry →
CGC Canopy Growth Corporation	D	51/100	—	—	—	+0.46%	$285.6M	/cgc-vs-tlry →
USNA USANA Health Sciences Inc.	C-	61/100	24.6x	78.3%	7.9%	-1.91%	$265.0M	/usna-vs-tlry →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001731348

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Tilray Brands Inc. (TLRY) reported GAAP revenue of $915.5M (+11.5% vs. FY2024 revenue of $821.3M , and +16.0% cumulative change since FY2023) , GAAP net income of -$121.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (+26.9% YoY). On the balance sheet, TLRY closed FY2025 with $2.07B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$915.5M	-$121.4M	-$69.1M	-$69.1M	$2.07B	—
FY2024 (FY)	2025-05-31	$821.3M	-$2.19B	-$94.6M	-$94.6M	$3.40B	—
FY2023 (FY)	2024-05-31	$788.9M	-$245.0M	-$30.9M	-$30.9M	—	—

3. TLRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.64 (-1.86% 1D, market cap $390.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLRY ranks #888 in composite RQD confidence.

How does TLRY compare to OBIO and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M) and SNDL (SNDL Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLRY?

Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLRY trading relative to its 50-day, 200-day, and 52-week technical levels?

TLRY last traded at $2.64 (-1.86% on volume of 4,210,125 shares), positioning the stock -30.34% below its 50-day simple moving average ($3.79) and -51.74% below its 200-day simple moving average ($5.47). Across its 52-week range of $2.49 to $15.70, TLRY sits at the 1.1% percentile with a 14-day RSI of 18.4 (OVERSOLD (<32)) and an implied next-earnings move of ±10.9% ($2.35 to $2.93).

TLRY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TLRY insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TLRY leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: TLRY RQD Cockpit TLRY 12M Forecast TLRY Earnings & Move TLRY Dividends & DRIP TLRY Insiders & 13F TLRY Whale Options TLRY Profit Sankey TLRY News & Why